Evolent Health Statistics
Total Valuation
Evolent Health has a market cap or net worth of $444.30 million. The enterprise value is $1.29 billion.
Important Dates
The last earnings date was Thursday, May 7, 2026, before market open.
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Evolent Health has 112.48 million shares outstanding. The number of shares has decreased by -1.41% in one year.
| Current Share Class | 112.48M |
| Shares Outstanding | 112.48M |
| Shares Change (YoY) | -1.41% |
| Shares Change (QoQ) | +0.26% |
| Owned by Insiders (%) | 1.44% |
| Owned by Institutions (%) | 84.81% |
| Float | 94.22M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 15.39 |
| PS Ratio | 0.24 |
| Forward PS | 0.17 |
| PB Ratio | 1.12 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 75.39 |
| P/OCF Ratio | 13.34 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 17.32, with an EV/FCF ratio of 218.51.
| EV / Earnings | n/a |
| EV / Sales | 0.68 |
| EV / EBITDA | 17.32 |
| EV / EBIT | n/a |
| EV / FCF | 218.51 |
Financial Position
The company has a current ratio of 1.32, with a Debt / Equity ratio of 2.49.
| Current Ratio | 1.32 |
| Quick Ratio | 1.20 |
| Debt / Equity | 2.49 |
| Debt / EBITDA | 12.53 |
| Debt / FCF | 167.22 |
| Interest Coverage | -0.25 |
Financial Efficiency
Return on equity (ROE) is -65.11% and return on invested capital (ROIC) is -1.31%.
| Return on Equity (ROE) | -65.11% |
| Return on Assets (ROA) | -0.45% |
| Return on Invested Capital (ROIC) | -1.31% |
| Return on Capital Employed (ROCE) | -1.09% |
| Weighted Average Cost of Capital (WACC) | 6.28% |
| Revenue Per Employee | $449,720 |
| Profits Per Employee | -$127,091 |
| Employee Count | 4,200 |
| Asset Turnover | 0.83 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -686,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -48.30% in the last 52 weeks. The beta is 0.84, so Evolent Health's price volatility has been lower than the market average.
| Beta (5Y) | 0.84 |
| 52-Week Price Change | -48.30% |
| 50-Day Moving Average | 3.22 |
| 200-Day Moving Average | 5.00 |
| Relative Strength Index (RSI) | 57.92 |
| Average Volume (20 Days) | 2,697,950 |
Short Selling Information
The latest short interest is 14.94 million, so 13.29% of the outstanding shares have been sold short.
| Short Interest | 14.94M |
| Short Previous Month | 16.20M |
| Short % of Shares Out | 13.29% |
| Short % of Float | 15.86% |
| Short Ratio (days to cover) | 5.38 |
Income Statement
In the last 12 months, Evolent Health had revenue of $1.89 billion and -$533.78 million in losses. Loss per share was -$4.71.
| Revenue | 1.89B |
| Gross Profit | 381.19M |
| Operating Income | -16.29M |
| Pretax Income | -497.21M |
| Net Income | -533.78M |
| EBITDA | 74.36M |
| EBIT | -16.29M |
| Loss Per Share | -$4.71 |
Full Income StatementBalance Sheet
The company has $142.03 million in cash and $985.43 million in debt, with a net cash position of -$843.40 million or -$7.50 per share.
| Cash & Cash Equivalents | 142.03M |
| Total Debt | 985.43M |
| Net Cash | -843.40M |
| Net Cash Per Share | -$7.50 |
| Equity (Book Value) | 396.39M |
| Book Value Per Share | 3.52 |
| Working Capital | 120.78M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $33.29 million and capital expenditures -$27.40 million, giving a free cash flow of $5.89 million.
| Operating Cash Flow | 33.29M |
| Capital Expenditures | -27.40M |
| Depreciation & Amortization | 90.65M |
| Net Borrowing | -93.44M |
| Free Cash Flow | 5.89M |
| FCF Per Share | $0.05 |
Full Cash Flow StatementMargins
Gross margin is 20.18%, with operating and profit margins of -0.86% and -26.29%.
| Gross Margin | 20.18% |
| Operating Margin | -0.86% |
| Pretax Margin | -26.32% |
| Profit Margin | -26.29% |
| EBITDA Margin | 3.94% |
| EBIT Margin | -0.86% |
| FCF Margin | 0.31% |
Dividends & Yields
Evolent Health does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 1.41% |
| Shareholder Yield | 1.41% |
| Earnings Yield | -120.14% |
| FCF Yield | 1.33% |
Analyst Forecast
The average price target for Evolent Health is $5.75, which is 45.57% higher than the current price. The consensus rating is "Buy".
| Price Target | $5.75 |
| Price Target Difference | 45.57% |
| Analyst Consensus | Buy |
| Analyst Count | 16 |
| Revenue Growth Forecast (5Y) | 19.09% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Evolent Health has an Altman Z-Score of 0.38 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.38 |
| Piotroski F-Score | 4 |
